^(131)I-chTNT-mediated radioimmunotherapy for non-uptaking ^(131)I pulmonary metastases from differentiated thyroid carcinoma  

作　　者：GAO Shi JI Tiefeng WEN Qiang CHEN Bin MA Qingjie CHEN Zuowei LIU Lin 

机构地区：[1]China-Japan Union Hospital,Jilin University [2]Department of Nuclear Medicine,People's Hospital of Shenzhen

出　　处：《Nuclear Science and Techniques》2013年第6期56-60,共5页核技术（英文）

基　　金：Supported by the National Natural Science Foundation of China(NSFC)projects(No.81271606);the Research Fund of Science and Technology Department of Jilin Province(Nos.201015185 and 201201041);the Research Fund of Shenzhen Sci-tech Department of Guangdong Province(No.201102154)

摘　　要：In this paper,the safety and efficacy of 131I-labeled mouse/human chimeric monoclonal antibody(131I-chTNT)-mediated radioimmunotherapy are evaluated because the patients have non-uptaking 131I pulmonary metastases from differentiated thyroid carcinoma(DTC).The 16 patients were injected intravenously by 29.6±3.7MBq·kg–1 using 131I-chTNT.The chest computer tomography was performed before treatment,as well as 28 and 70days after treatment.Responses and safety were assessed during the treatment.The results show that the 131I-chTNT infusion was well tolerated with the 12.5%complete response,18.8%partial response,25.0%progressive disease,and the 43.8%stable disease,indicating that most treatment-related adverse effects are mild transient and reversible.The131I-chTNT is promising for patients with non-uptaking the 131I pulmonary metastases from DTC.In this paper, the safety and efficacy of 131I-labeled mouse/human chimeric monoclonal antibody （131I-chTNT）-mediated radioimmunotherapy are evaluated because the patients have non-uptaking 131I pulmonary metastases from differentiated thyroid carcinoma （DTC）. The 16 patients were injected intravenously by 29.6±3.7 MBq＇kg 1 using 131I-chTNT. The chest computer tomography was performed before treatment, as well as 28 and 70 days after treatment. Responses and safety were assessed during the treatment. The results show that the 131I-chTNT infusion was well tolerated with the 12.5% complete response, 18.8% partial response, 25.0% progressive disease, and the 43.8% stable disease, indicating that most treatment-related adverse effects are mild transient and reversible. The 131I-chTNT is promising for patients with non-uptaking the 131I pulmonary metastases from DTC.

关 键 词：免疫治疗 甲状腺癌 吸收 分化 放射 介导 肺 不良反应 

分 类 号：R730.55[医药卫生—肿瘤]